Clinical Trial ResultsObefazimod exceeded investor and company expectations on the FDA primary endpoint of clinical remission, achieving significant benefits across all primary and key secondary endpoints.
Market PotentialObefazimod now has the most compelling late-stage clinical profile for a novel oral agent in ulcerative colitis with potential to address a clear unmet need in the massive ~$30bn market for IBD therapeutics.
Regulatory ProspectsBoth doses of obefazimod met European Medicines Agency co-primary endpoints, strengthening confidence in the potential for regulatory approval.